NIH re­jects an­oth­er at­tempt to 'march-in' on Astel­las' prostate can­cer drug over ex­ces­sive price

The Na­tion­al In­sti­tutes of Health has again de­clined to use so-called “march-in” rights to low­er the price of Astel­las and Pfiz­er’s prostate can­cer drug Xtan­di de­spite be­ing in­vent­ed at UCLA with grants from the US Army and NIH.

“Giv­en the re­main­ing patent life and the lengthy ad­min­is­tra­tive process in­volved for a march-in pro­ceed­ing, NIH does not be­lieve that use of the march-in au­thor­i­ty would be an ef­fec­tive means of low­er­ing the price of the drug,” NIH told prostate can­cer pa­tients Robert Sachs and Clare Love, in a let­ter shared with End­points News. The in­sti­tutes’ analy­ses found Xtan­di “to be wide­ly avail­able to the pub­lic,” an in­di­ca­tion that there was not a press­ing need for the US to act.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER